{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:06:55Z","timestamp":1790417215017,"version":"4.1.0"},"reference-count":37,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2008,3,1]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> To test whether nelarabine is an effective agent for indolent leukemias and to evaluate whether there is a relationship between cellular pharmacokinetics of the analog triphosphate and clinical responses. <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> Thirty-five patients with relapsed\/refractory leukemias (n = 24, B-cell chronic lymphocytic leukemia and n = 11, T-cell prolymphocytic leukemia) were entered onto three different protocols. For schedule A, patient received nelarabine daily for 5 days, whereas for schedule B, nelarabine was administered on days 1, 3, and 5. Schedule C was similar to schedule B except that fludarabine was also infused. Plasma and cellular pharmacokinetics were studied during the first cycle. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> Responses were achieved in 20%, 15%, and 63% of patients receiving schedule A, B, and C, respectively. Histologic category, number of prior therapies, and fludarabine refractoriness did not influence the response rate. The most common nonhematologic toxicity was peripheral neuropathy. Grade 4 neutropenia and thrombocytopenia complicated 23% and 26% of courses respectively, and were significantly more frequent among patients with pre-existing marrow failure. Pharmacokinetics of plasma nelarabine and arabinosylguanine (ara-G) and of cellular ara-G triphosphate (ara-GTP) were similar in the two groups of diagnoses, and the elimination of ara-GTP from leukemia cells was slow (median, &gt; 24 hours). The median peak intracellular concentrations of ara-GTP were significantly different (P = .0003) between responders (440 \u03bcmol\/L; range, 35 to 1,438 \u03bcmol\/L; n = 10) and nonresponders (50 \u03bcmol\/L; range, 22 to 178 \u03bcmol\/L; n = 15). <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> Nelarabine is an effective regimen against indolent leukemias, and combining it with fludarabine was most promising. Determination of tumor cell ara-GTP levels may provide a predictive test for response to nelarabine. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2007.14.1986","type":"journal-article","created":{"date-parts":[[2008,2,28]],"date-time":"2008-02-28T23:43:07Z","timestamp":1204242187000},"page":"1098-1105","source":"Crossref","is-referenced-by-count":39,"title":["Phase I Trial of Nelarabine in Indolent Leukemias"],"prefix":"10.1200","volume":"26","author":[{"given":"Varsha","family":"Gandhi","sequence":"first","affiliation":[{"name":"From the Departments of Experimental Therapeutics and Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX; and GlaxoSmithKline, Research Triangle Park, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine","family":"Tam","sequence":"additional","affiliation":[{"name":"From the Departments of Experimental Therapeutics and Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX; and GlaxoSmithKline, Research Triangle Park, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"O'Brien","sequence":"additional","affiliation":[{"name":"From the Departments of Experimental Therapeutics and Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX; and GlaxoSmithKline, Research Triangle Park, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxanne C.","family":"Jewell","sequence":"additional","affiliation":[{"name":"From the Departments of Experimental Therapeutics and Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX; and GlaxoSmithKline, Research Triangle Park, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Carlos O.","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"From the Departments of Experimental Therapeutics and Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX; and GlaxoSmithKline, Research Triangle Park, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Lerner","sequence":"additional","affiliation":[{"name":"From the Departments of Experimental Therapeutics and Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX; and GlaxoSmithKline, Research Triangle Park, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Plunkett","sequence":"additional","affiliation":[{"name":"From the Departments of Experimental Therapeutics and Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX; and GlaxoSmithKline, Research Triangle Park, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Keating","sequence":"additional","affiliation":[{"name":"From the Departments of Experimental Therapeutics and Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX; and GlaxoSmithKline, Research Triangle Park, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.4.679"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-12-4828"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.051"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2395"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.1.116"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199732020-00003"},{"key":"R7","unstructured":"Albertioni F, Lindemalm S, Reichelova V, et al: Pharmacokinetics of cladribine in plasma and its 5\u2032-monophosphate and 5\u2032-triphosphate in leukemic cells of patients with chronic lymphocytic leukemia. Clin Cancer Res 4:653,1998-658,"},{"key":"R8","unstructured":"Gandhi V, Keating MJ, Estey E, et al: Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia. Cancer Res 52:897,1992-903,"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.3109\/10428199309147356"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/82.17.1416"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.2.168"},{"key":"R12","doi-asserted-by":"crossref","unstructured":"Giblett ER, Ammann AJ, Wara DW, et al: Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity. Lancet 1:1010,1975-1013,","DOI":"10.1016\/S0140-6736(75)91950-9"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1016\/S0925-4439(02)00073-X"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-1309"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-007468"},{"key":"R16","unstructured":"Lambe CU, Averett DR, Paff MT, et al: 2-Amino-6-methoxypurine arabinoside: An agent for T-cell malignancies. Cancer Res 55:3352,1995-3356,"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1021\/bi00889a004"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6215(00)80531-5"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.11.3607"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.8.2142"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.199"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.426"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-056754"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0606"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1933"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.5.995"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(00)00303-0"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(89)90500-5"},{"key":"R30","doi-asserted-by":"crossref","unstructured":"Wang L, Karlsson A, Arn\u00e9r ESJ, et al: Substrate specificity of mitochondrial 2\u2032-deoxyguanosine kinase: Efficient phosphorylation of 2-chlorodeoxyadenosine. J Biol Chem 268:22847,1993-22852,","DOI":"10.1016\/S0021-9258(18)41605-5"},{"key":"R31","doi-asserted-by":"crossref","unstructured":"Krenitsky TA, Tuttle JV, Koszalka GW, et al: Deoxycytidine kinase from calf thymus: Substrate and inhibitor specificity. J Biol Chem 251:4055,1976-4061,","DOI":"10.1016\/S0021-9258(17)33354-9"},{"key":"R32","unstructured":"Rodriguez CO Jr, Mitchell BS, Eriksson S, et al: Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. Cancer Res 62:3100,2002-3105,"},{"key":"R33","unstructured":"Shewach DS, Daddona PE, Ashcraft E, et al: Metabolism and selective cytotoxicity of 9-\u03b2-D-arabinofuranosylguanine in human lymphoblasts. Cancer Res 45:1008,1985-1014,"},{"key":"R34","unstructured":"Verhoef V, Fridland A: Metabolic basis of arabinonucleoside selectivity for human leukemic T- and B-lymphoblasts. Cancer Res 45:3646,1985-3650,"},{"key":"R35","unstructured":"Shewach DS, Mitchell BS: Differential metabolism of 9-\u03b2-arabinofuranosylguanine in human leukemic cells. Cancer Res 49:6498,1989-6502,"},{"key":"R36","doi-asserted-by":"publisher","DOI":"10.1080\/1042819021000006547"},{"key":"R37","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.0680"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2007.14.1986","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T00:14:56Z","timestamp":1653524096000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2007.14.1986"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3,1]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2008,3,1]]}},"alternative-id":["10.1200\/JCO.2007.14.1986"],"URL":"https:\/\/doi.org\/10.1200\/jco.2007.14.1986","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3,1]]}}}